The project 'Beta-AARC: Cohort study for the identification of blood biomarkers in the population with subjective cognitive decline' aims to know the factors involved in the onset of the biological process of Alzheimer's disease and biomarkers that predict its evolution.
The study will include 200 participants between the ages of 55 and 80 who experience a decline in memory or other cognitive abilities, such as attention, planning ability, and orientation. Participants will undergo a series of clinical, cognitive, imaging tests and determinations of biomarkers in blood and cerebrospinal fluid.
Beta AARC aims to advance the early detection of blood biomarkers that represent the pathophysiological changes related to Alzheimer’s in people who experience a subjective deterioration of memory. Finding these markers will help predict the onset of the disease long before the first symptoms appear and the brain damage is irreversible, and propose effective preventive and therapeutic actions.
On the other hand, the study aims to deepen the knowledge of the factors that influence the onset of the disease and how mental abilities and the brain are affected by other aspects, such as the symptoms of the affected person and the age in which it appears.